PureTech Health appoints interim CEO Robert Lyne
Ella Day | July 24, 2025 | Appointment | Research and Development | Corporate, PureTech Health, board of directors, chief portfolio officer, interim CEO
PureTech Health has announced the departure of chief executive officer (CEO) Bharatt Chowrira, who has stepped down from his role and as a member of the board of directors. Robert Lyne, who is currently chief portfolio officer, has been appointed interim CEO with immediate effect.
Lyne, who joined PureTech in January 2024, brings significant experience from the UK life sciences sector, having previously served as CEO of Arix Bioscience. He will lead the company through its next phase of growth, working closely with the board to advance PureTech’s clinical programmes.
Sharon Barber-Lui, interim chair of the board, thanked Chowrira for his leadership over the past eight years: “We remain focused on driving shareholder value and Rob’s operational and capital markets experience will be key as he collaborates with the board and engages with shareholders.”
Commenting on his new role, Lyne said: “I’m honoured to take on the role of interim CEO. PureTech has a high-value portfolio, and I look forward to building on the momentum we’ve generated to deliver meaningful milestones for patients and shareholders.”
Chowrira added: “It’s been a privilege to be part of PureTech’s journey. I’m incredibly proud of what we’ve achieved and confident in the team’s future.”
PureTech is a clinical-stage biotherapeutics company focused on developing medicines for serious diseases. It has produced 29 therapeutic candidates, including three approved by the US Food and Drug Administration.
Ella Day
24/7/25
Related Content
PureTech Health launches Seaport Therapeutics
PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to …
PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial
Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine …
Allergan shareholders reject proposal to split roles of chairman and CEO
Allergan shareholders have rejected a proposal to immediately separate the roles of CEO and chairman, …
